title: Statin in combination with β-blocker therapy reduces postoperative stroke after coronary artery bypass graft surgery.
abstract: BACKGROUND
  Statin therapy prior to coronary artery bypass surgery (CABG) has been shown to prevent perioperative events such as myocardial infarction and perioperative death. The effect of statin therapy as a preventive treatment to decrease the stroke risk unrelated to cardiac surgery is also documented. In the setting of CABG, we have found no studies reporting a preventive effect of statin therapy on neurologic outcome.
  
  
  METHODS
  We analyzed 6,813 patients treated by CABG surgery at our institution between 1995 and 2005 for which complete medication history including all drugs taken before and after surgery was available. We analyzed the risk factors for postoperative stroke using a multiple logistic regression analysis, more specifically looking at the effect of preoperative treatment with statin, aspirin, β-blockers, and angiotensin-converting enzyme inhibitors, alone or in combination.
  
  
  RESULTS
  At 30 days postoperative, 94 patients suffered a new documented stroke (1.4%). Hypertension, carotid disease, diabetes, and age were all associated with a greater risk of postoperative stroke. When analyzing the four groups of drug therapy, none of the medications alone affected the stroke rate. However, upon multivariable analysis the combination of statin and β-blockers gave an odds ratio of 0.377, suggesting a strong protective effect.
  
  
  CONCLUSIONS
  Beta-blockers combined with statin confer a protective effect for stroke after CABG.
authors.affiliation: Department of Cardiac Surgery, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. denis.bouchard@icm-mhi.org
authors.forename: Denis
authors.initials: D
authors.lastname: Bouchard
authors.forename: Michel
authors.initials: M
authors.lastname: Carrier
authors.forename: Philippe
authors.initials: P
authors.lastname: Demers
authors.forename: Raymond
authors.initials: R
authors.lastname: Cartier
authors.forename: Michel
authors.initials: M
authors.lastname: Pellerin
authors.forename: Louis P
authors.initials: LP
authors.lastname: Perrault
authors.forename: Jean
authors.initials: J
authors.lastname: Lambert
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011300:Preoperative Care; D011379:Prognosis; D011792:Quebec / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000319:Adrenergic beta-Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors